Kaum Fortschritte im Kampf gegen resistente Keime
Die Zeit covers the results of the second Antimicrobial Resistance Benchmark. The article's takeaway headline from the report is that, while progress is happening, and some companies are stepping up, others are either maintaining course, or even backing away from the anti-infectives space.
Sourced from Reuters, the article compares the pipeline of new drugs to that of the first Antimicrobial Resistance Benchmark in 2018, describing the pipeline for new drugs as small, with only 51 potential treatments in late-stage clinical trials as reported.
The article features a quote from Jayasree Iyer, executive director of the Access to Medicine Foundation, in response to this minimal change:
“This second benchmark provides a reality check, the progress we see is being overshadowed by our increasing reliance on just a handful of companies.”
It concludes with a summary of the top performing companies reported in the Benchmark, highlighting their progress and where gaps still remain.